← Back to all trials
Not Yet Recruiting
NCT07788105
Efficacy and Safety of Lanoracopan in the Treatment of PNH
Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Enrollment: 90
Sponsor: Peking Union Medical College Hospital
Summary
This study aimed to evaluate the efficacy and safety of Lanoracopan Hydrochloride in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Eligibility Criteria
Inclusion Criteria:
1. Age 18-75 years.
2. Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) meeting any of the following conditions:
* Newly diagnosed PNH with active hemolysis (hemoglobin \[Hb\] \1.5×upper limit of normal \[ULN\]);
* Receiving a stable regimen of complement C5 monoclonal antibody (eculizumab) at standard dose and interval for ≥3 months, with Hb still \
Source: ClinicalTrials.gov (NCT07788105). StuddyBuddy aggregates publicly available trial information.
